Icariin, astragaloside IV and puerarin mixture salvages synaptic loss by enhancing mitochondrial biogenesis: A multi-target strategy for Alzheimer’s disease therapy - 23/04/26
Abstract |
Objective |
This study aimed to elucidate the potential mechanism by which the Icariin, astragaloside IV and puerarin (Ying-Huang-Ge, YHG) mixture regulates mitochondrial-synaptic homeostasis in Alzheimer’s disease (AD) MOD mice through the Glycogen Synthase Kinase-3β (GSK-3β)/Peroxisome Proliferator-Activated Receptor γ Coactivator-1α (PGC-1α) signaling axis.
Methods |
Thirty 5-month-old male APP/PS1 mice were randomly divided into the MOD group, the YHG treatment group (YHG), and the Donepezil treatment group (DNP) (n = 10 per group). Ten age-matched male C57BL/6 J mice served as the CON group. Following two months of continuous administration, cognitive function was assessed using the Morris Water Maze (MWM) and Novel Object Recognition (NOR) tests. Dendritic spine density in the hippocampal CA1 region was evaluated via Golgi staining, and ultrastructural changes were examined using transmission electron microscopy (TEM). Hippocampal levels of adenosine triphosphate (ATP), malondialdehyde (MDA), and superoxide dismutase (SOD) were measured using biochemical assay kits. Protein expression levels of GSK-3β, p-GSK-3β (Ser9), PGC-1α, mitochondrial functional proteins (NRF-1, TFAM), and synaptic plasticity-related proteins (PSD95, SYN) were determined by Western blot.
Results |
Compared with the CON group, the MOD group exhibited significantly impaired learning and memory capabilities, reduced dendritic spine density in the hippocampal CA1 region, and disrupted synaptic ultrastructure. Mitochondria displayed pathological changes, including swelling and vacuolization. Furthermore, ATP and SOD levels were significantly decreased, while MDA content was elevated. Western blot analysis revealed increased total GSK-3β expression and significantly decreased expression of p-GSK-3β (Ser9), PGC-1α, downstream mitochondrial biogenesis proteins (NRF-1, TFAM), and synaptic proteins (PSD95, SYN). Intervention with YHG significantly ameliorated these cognitive deficits, mitigated pathological damage to mitochondria and synapses, and reversed the abnormal molecular expression profiles.
Conclusion |
The YHG ameliorates cognitive dysfunction and attenuates synaptic impairment in APP/PS1 mice. The underlying mechanism may involve the inhibition of GSK-3β activity, which subsequently activates PGC-1α-mediated mitochondrial biogenesis, enhances mitochondrial quality, and mitigates oxidative stress, ultimately leading to the restoration of synaptic structural integrity.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
YHG exerts neuroprotective effects by modulating the GSK-3β/PGC-1α signaling axis to restore the mitochondrial-synaptic functional unit. Specifically, YHG promotes the inhibitory phosphorylation of GSK-3β at Ser9, thereby relieving the suppression of PGC-1α and activating its downstream effectors, NRF-1 and TFAM. This signaling cascade reactivates mitochondrial biogenesis and preserves cristae integrity, leading to enhanced ATP production and attenuated oxidative stress. These bioenergetic improvements provide the metabolic foundation for synaptic structural remodeling, characterized by the upregulation of PSD-95 and SYN, alongside increased dendritic spine density. Ultimately, the integration of metabolic revitalization and synaptic restoration culminates in the significant amelioration of cognitive impairment in AD mice.
YHG exerts neuroprotective effects by modulating the GSK-3β/PGC-1α signaling axis to restore the mitochondrial-synaptic functional unit. Specifically, YHG promotes the inhibitory phosphorylation of GSK-3β at Ser9, thereby relieving the suppression of PGC-1α and activating its downstream effectors, NRF-1 and TFAM. This signaling cascade reactivates mitochondrial biogenesis and preserves cristae integrity, leading to enhanced ATP production and attenuated oxidative stress. These bioenergetic improvements provide the metabolic foundation for synaptic structural remodeling, characterized by the upregulation of PSD-95 and SYN, alongside increased dendritic spine density. Ultimately, the integration of metabolic revitalization and synaptic restoration culminates in the significant amelioration of cognitive impairment in AD mice. Le texte complet de cet article est disponible en PDF.
Highlight |
• | YHG mixture alleviates cognitive deficits in APP/PS1 transgenic mice. |
• | YHG salvages hippocampal synaptic loss and restores dendritic spine density. |
• | YHG treatment reactivates PGC-1α-mediated mitochondrial biogenesis. |
• | Mitochondrial repair by YHG provides the energy for synaptic structural remodeling. |
• | The neuroprotective effect of YHG involves modulating the GSK-3β/PGC-1α axis. |
Keywords : Alzheimer's disease, Mitochondrial dysfunction, Oxidative Stress, Synapse, GSK-3β/PGC-1α Signaling Axis, APP/PS1
Plan
Vol 198
Article 119320- mai 2026 Retour au numéro
Article précédent
- Medical gas plasma modulates in vitro keratinocyte redox signaling and secretory profiles in actinic keratosis and squamous cell carcinoma
- Lauren McKeever, Debora Singer, Caroline Scheufler, Zengyu Wang, Augusto Stancampiano, Eric Robert, Kristian Wende, Evelien Smits, Sander Bekeschus
- Pharmacological inhibition of CDK9 counteracts neuroinflammatory impairments in sepsis-associated encephalopathy
- Enrica Marzani, Gustavo Ferreira Alves, Alon Zemer, Chiara Rubeo, Eleonora Aimaretti, Elisa Porchietto, Leonardo Camillò, Patricio Israel Rivas Navarrete, Antonia Gurgone, Yulia Haim, Habib Muallem, Manuela Aragno, Assaf Rudich, Simona Federica Spampinato, Massimo Collino
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?